Eli Lilly Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly

LLY 1,031

-1.4%

9:56 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: lazarre who wrote (117)	4/6/1998 4:48:00 PM
From: Seni Sangrujee	Read Replies (1) of 642

RESEARCH ALERT-Eli Lilly upgrade detailed NEW YORK, April 6 (Reuters) - Furman Selz analyst James Flynn, in raising his rating on Eli Lilly and Co.'s shares to buy from hold, said the company's drug Evista may benefit from Zeneca Group Plc's (quote from Yahoo! UK & Ireland: ZEN.L) drug tamoxifen. Recent trial studies by the National Cancer Institute with tamoxifen showed a 45 percent reduction in breast cancer among women at higher risk, according to an article in the Philadelphia Inquirer. -- ''While Evista is presently approved for osteoporosis prevention and tamoxifen for the treatment of breast cancer, both products are thought to have roughly equivalent action on breasts and bone,'' Flynn wrote in a research report released on Monday. ''The primary difference between the products appears to be that tamoxifen, unlike Evista, can cause endometrial hyperplasia, a precursor to endometrial cancer.'' -- Lilly shares were up 2-5/16 to 60-7/8 in late trading Monday.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next